In the last fifty years, life expectancy has increased dramatically thanks to advances in science, medicine, and public awareness. The population is living longer, but with it comes the challenge of improving Healthy Life Expectancy.

Join our speakers in our innovative 3-part webinar series where they will openly discuss 3 key topics:

  • Therapeutic approaches for aging and age-related disease
  • Aging and precision medicine
  • Why older adults should not be underrepresented in clinical trials. 

If you wish to stream any or all of the parts of this webinar series, please register below. 

THERAPEUTIC APPROACHES FOR AGING
AND AGE-RELATED DISEASE-
OPPORTUNITIES AND CHALLENGES

Our first webinar will provide a high-level overview of therapeutic drug discovery and development for the treatment of aging and age-related disease. Key topics will include our current understanding of some of the biological processes that drive cellular aging and illustrate how we now have the real prospect of offsetting the aging process through pharmacological intervention. We will review some of the targets and systems that have been explored to date, especially those that have been investigated in the clinic.

Speaker

Steven England_InCircle

Steve England

SVP, in vitro Biology at Evotec

 

AGING AND PRECISION MEDICINE

Although the over-arching aim of aging research is life extension, a more realistic goal is improvement in health span. However, one of the major challenges in the field is the accurate assessment of biological versus chronological age. Identification of biomarkers that reflect the age-related decline in biological fitness will be vital if we are to assess the efficacy of putative therapeutics both in clinical development, but also in preclinical models. Join us to discuss some of the potential candidates which could form a biomarker ‘fingerprint’ as indicators of clinical efficacy.

Speaker

Elizabeth van der Kam_InCircle

Elizabeth van der Kam,

SVP, Translational Biomarkers & HD Research at Evotec

 

THE BOOMER BURDEN: WHY OLDER ADULTS SHOULD NOT BE UNDERREPRESENTED
IN CLINICAL TRIALS

Our final webinar in this series will provide a high-level comparison between the healthcare needs of the old-old (older than 75 years) and their representation in clinical trials. Key topics will include several unique characteristics of this population, including common chronic health concerns, comorbidities, healthcare utilization, and concomitant medications. We will also review data from open-source clinical trial statistics outlining the lack of representation of the old-old in clinical trials, despite this population perhaps receiving more drug treatments than any other cohort. We will discuss barriers for clinical trial inclusion for the old-old as well as what can realistically be overcome, and lastly, raise questions for discussions such as, “should older adults be included in pivotal trials?” If so then “Who should be responsible for driving this effort? Regulators, Sponsors, etc.?

Speaker

Leese Gentry_InCircle

Leesa Gentry

SVP, Global Clinical Development